Sensus Healthcare (NASDAQ:SRTS) Given New $8.00 Price Target at HC Wainwright

Key Points

• HC Wainwright has decreased its price target for Sensus Healthcare from $12.00 to $8.00, maintaining a "buy" rating, suggesting a potential upside of 151.57% from the last close.
• Sensus Healthcare's stock saw an 8.1% decline on Tuesday, trading at $3.18, well below its 52-week high of $9.33.
• The company reported a loss of ($0.06) earnings per share for its latest quarterly earnings, missing analyst expectations and generating revenues of $7.32 million, lower than the anticipated $9.30 million.

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) had its price objective reduced by stock analysts at HC Wainwright from $12.00 to $8.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. HC Wainwright's price target points to a potential upside of 151.57% from the company's previous close.

SRTS has been the topic of a number of other reports. Lake Street Capital cut their target price on shares of Sensus Healthcare from $13.00 to $6.00 and set a "buy" rating on the stock in a report on Friday. Wall Street Zen cut shares of Sensus Healthcare from a "hold" rating to a "sell" rating in a report on Sunday, June 22nd. Finally, Maxim Group cut their target price on shares of Sensus Healthcare from $14.00 to $10.00 and set a "buy" rating on the stock in a report on Monday, May 19th.

Sensus Healthcare Stock Down 8.1%

Shares of Sensus Healthcare stock opened at $3.18 on Tuesday. Sensus Healthcare has a 52-week low of $3.10 and a 52-week high of $9.33. The company has a 50 day moving average of $4.81 and a 200 day moving average of $4.96. The company has a market capitalization of $52.28 million, a P/E ratio of -53.00 and a beta of 1.34.

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.01 by ($0.07). Sensus Healthcare had a negative return on equity of 1.56% and a negative net margin of 2.26%. The firm had revenue of $7.32 million during the quarter, compared to analysts' expectations of $9.30 million. As a group, research analysts anticipate that Sensus Healthcare will post 0.32 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Sensus Healthcare

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC grew its position in Sensus Healthcare by 2.5% in the 2nd quarter. Geode Capital Management LLC now owns 153,917 shares of the company's stock valued at $730,000 after buying an additional 3,766 shares during the last quarter. Vise Technologies Inc. purchased a new stake in shares of Sensus Healthcare during the 2nd quarter worth $52,000. Evernest Financial Advisors LLC purchased a new stake in shares of Sensus Healthcare during the 2nd quarter worth $255,000. Sachetta LLC boosted its position in shares of Sensus Healthcare by 3.0% during the 2nd quarter. Sachetta LLC now owns 128,675 shares of the company's stock worth $610,000 after purchasing an additional 3,788 shares in the last quarter. Finally, Chapin Davis Inc. boosted its position in shares of Sensus Healthcare by 66.7% during the 2nd quarter. Chapin Davis Inc. now owns 25,000 shares of the company's stock worth $118,000 after purchasing an additional 10,000 shares in the last quarter. 25.30% of the stock is currently owned by hedge funds and other institutional investors.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.